Physician profile
Danielle R Macabobby
NPI 1215997960
$576.54
in general payments reported to CMS, 2019-2025
10 companies · $15.65 in 2025
The $15.65 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $73.58 · 2021: $109 · 2022: $38.94 · 2023: $58.56 · 2024: $99.14 · 2025: $15.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $118.31 | 2019-2024 | |
| Pfizer INC. | $108.46 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $97.43 | 2019-2024 | Vaxelis, Gardasil 9, Gardasil |
| Ironshore Pharmaceuticals INC. | $52.58 | 2019 | |
| Glaxosmithkline, LLC. | $46.25 | 2019-2025 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $44.89 | 2019-2021 | |
| Sobi, INC | $33.89 | 2021-2022 | |
| Tris Pharma INC | $33.81 | 2019-2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $22.60 | 2024 | Qelbree |
| Shire North American Group INC | $18.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Macabobby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.